VVP
VRTX icon

Venture Visionary Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Venture Visionary Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$491K Buy
989
+301
+44% +$133K 0.01% 476
2026
Q1 		$307K Sell
688
-466
-40% -$217K 0.01% 508
2025
Q4 		$523K Buy
1,154
+197
+21% +$84.9K 0.02% 423
2025
Q3 		$375K Buy
957
+263
+38% +$110K 0.01% 476
2025
Q2 		$309K Buy
694
+5
+0.7% +$2.3K 0.01% 479
2025
Q1 		$334K Sell
689
-1
-0.1% -$466 0.01% 450
2024
Q4 		$278K Buy
690
+4
+0.6% +$1.85K 0.01% 465
2024
Q3 		$319K Sell
686
-1
-0.1% -$480 0.01% 446
2024
Q2 		$322K Buy
687
+14
+2% +$6.08K 0.01% 450
2024
Q1 		$281K Sell
673
-9
-1% -$3.81K 0.01% 459
2023
Q4 		$277K Buy
682
+10
+1% +$3.69K 0.01% 444
2023
Q3 		$234K Sell
672
-4
-0.6% -$1.4K 0.01% 447
2023
Q2 		$238K Sell
676
-5
-0.7% -$1.69K 0.01% 454
2023
Q1 		$215K Buy
+681
New +$204K 0.01% 461
2022
Q3 		– Sell
-339
Closed -$95.5K – 1521
2022
Q2 		$95.5K Buy
+339
New +$90.7K 0.01% 618

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Venture Visionary Partners's VRTX Position: Q2 2026 in Review

Venture Visionary Partners increased its Vertex Pharmaceuticals (VRTX) stake by 44% in Q2 2026, buying an estimated $133K and bringing the position to 989 shares worth $491K. The position accounts for 0.01% of the portfolio, ranked #476.

Venture Visionary Partners first reported a position in VRTX in Q2 2022 and has held it in 15 quarters since. The position peaked at $523K in Q4 2025. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Venture Visionary Partners held 989 shares of Vertex Pharmaceuticals worth $491K as of Q2 2026.
  • Venture Visionary Partners bought 301 Vertex Pharmaceuticals shares in Q2 2026, an estimated $133K.
  • Vertex Pharmaceuticals made up 0.01% of Venture Visionary Partners's portfolio in Q2 2026, its #476 holding.
  • Venture Visionary Partners first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
  • Venture Visionary Partners's Vertex Pharmaceuticals position peaked at $523K in Q4 2025.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Venture Visionary Partners's 13F filing for Q2 2026, filed 27 Jul 2026.